search
Back to results

CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery

Primary Purpose

Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion

Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Peripheral PTA with a drug coated balloon
Sponsored by
Chansu Vascular Technologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Femoral Artery Stenosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subject must be at least 18 years of age. Subject provides written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site. Subject must agree to undergo all clinical investigation plan-required follow-up visits and examinations. Subjects with symptomatic leg ischemia who do not respond favorably to Exercise Therapy or with symptoms that impact significantly daily life, requiring treatment of SFA or popliteal (P1 segment) artery. De novo or restenotic lesion(s) >70% within the SFA and popliteal arteries in a single limb which are ≥3 cm and ≤15 cm in cumulative total length (by visual estimation). Lesion must be at least 2 cm from any stented area. Subject is willing to comply with the required follow up visits, testing schedule and medication regimen. Successful wire crossing of lesion. Target vessel reference diameter ≥4 mm and ≤6 mm (by visual estimation). Target lesion(s) can be treated with a maximum of two (2) CVT Everolimus-coated PTA Catheters. At least one patent (less than 50% stenosis) tibio-peroneal run-off vessel confirmed by baseline angiography or prior MR angiography or CT angiography. Life expectancy >1 year Rutherford classification of 2, 3 or 4. Exclusion Criteria: Pregnant or lactating females. Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac or popliteal arteries. Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy. Known intolerance to study medications, everolimus or contrast agents. Doubts in the willingness or capability of the subject to allow follow-up examinations. Subject is actively participating in another investigational device or drug study. History of hemorrhagic stroke within 3 months of procedure. Previous or planned surgical or interventional procedure within 30 days of index procedure. Prior vascular surgery of the target lesion. Lesion length is <3 cm or >15 cm or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured. Known inadequate distal outflow. Significant inflow disease. Acute or sub-acute thrombus in target vessel. Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloons, brachytherapy, lithotripsy). Outflow arteries (distal popliteal, anterior or posterior tibial or peroneal arteries) with significant lesions (≥ 50% stenosis) may not be treated during the same procedure. Treatment of the contralateral limb during the same procedure or within 30 days of the study procedure. Rutherford classification of 0, 1, 5 or 6 Presence of prohibitive calcification that precludes adequate PTA treatment. Subjects held in custody in an institution by official or court order. Subject is not covered by any medical insurance coverage.

Sites / Locations

  • Polyclinique Les Fleurs
  • Hôpital Paris Saint Joseph
  • Hôpital Nord Laennec - CHU de Nantes
  • Clinique Pasteur
  • Vivantes Klinikum Neukölln
  • Jüdisches Krankenhaus Berlin
  • DIAKO Krankenhaus Flensburg
  • Romed Klinikum Rosenheim

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Everolimus-coated balloon

Arm Description

Treatment of occlusion or stenosis in Superficial Femoral Artery and Proximal Popliteal Artery with drug-coated balloon

Outcomes

Primary Outcome Measures

Freedom of Major Adverse Event (MAE) rate
Composite rate of cardiovascular death, index limb amputation and ischemia-driven target lesion revascularization (TLR).
Patency
Freedom from restenosis as determined by duplex ultrasonography (DUS) (peak systolic velocity ratio (PSVR) ≤2.4 or ≤50% stenosis) and freedom from ischemia-driven target lesion revascularization (TLR).

Secondary Outcome Measures

Rate of MAE
Composite rate of cardiovascular death, index limb amputation and ischemia-driven Target Lesion Revascularization (TLR).
Patency
Freedom from clinically driven TLR and duplex ultrasonography detected restenosis (ultrasound peak systolic velocity ratio ≤ 2.4 or stenosis ≤50%)

Full Information

First Posted
January 27, 2023
Last Updated
February 15, 2023
Sponsor
Chansu Vascular Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT05734157
Brief Title
CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery
Official Title
Chansu Vascular Technologies Everolimus-Coated Balloon Percutaneous Transluminal Angioplasty Catheter First-in-Human Clinical Investigation
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 17, 2022 (Actual)
Primary Completion Date
February 3, 2023 (Actual)
Study Completion Date
September 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chansu Vascular Technologies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The CVT-SFA Trial investigates the inhibition of restenosis using the CVT Everolimus-coated PTA Catheter in the treatment of de-novo occluded/ stenotic or re-occluded/restenotic superficial femoral or popliteal arteries.
Detailed Description
The CVT-SFA Trial is a prospective, multi-center, open, single arm study enrolling subjects with de-novo or post-PTA occluded/stenotic or re-occluded/ restenotic lesions (excluding in-stent lesions) ≤150mm in length in femoropopliteal arteries with reference vessel diameters of 4-6mm, receiving up to two (2) CVT Everolimus-coated PTA Catheters to establish blood flow and to maintain vessel patency.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
76 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Everolimus-coated balloon
Arm Type
Experimental
Arm Description
Treatment of occlusion or stenosis in Superficial Femoral Artery and Proximal Popliteal Artery with drug-coated balloon
Intervention Type
Device
Intervention Name(s)
Peripheral PTA with a drug coated balloon
Intervention Description
Peripheral artery angioplasty
Primary Outcome Measure Information:
Title
Freedom of Major Adverse Event (MAE) rate
Description
Composite rate of cardiovascular death, index limb amputation and ischemia-driven target lesion revascularization (TLR).
Time Frame
6 months post-procedure
Title
Patency
Description
Freedom from restenosis as determined by duplex ultrasonography (DUS) (peak systolic velocity ratio (PSVR) ≤2.4 or ≤50% stenosis) and freedom from ischemia-driven target lesion revascularization (TLR).
Time Frame
6 months post procedure
Secondary Outcome Measure Information:
Title
Rate of MAE
Description
Composite rate of cardiovascular death, index limb amputation and ischemia-driven Target Lesion Revascularization (TLR).
Time Frame
One year post-procedure
Title
Patency
Description
Freedom from clinically driven TLR and duplex ultrasonography detected restenosis (ultrasound peak systolic velocity ratio ≤ 2.4 or stenosis ≤50%)
Time Frame
12 months post procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject must be at least 18 years of age. Subject provides written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site. Subject must agree to undergo all clinical investigation plan-required follow-up visits and examinations. Subjects with symptomatic leg ischemia who do not respond favorably to Exercise Therapy or with symptoms that impact significantly daily life, requiring treatment of SFA or popliteal (P1 segment) artery. De novo or restenotic lesion(s) >70% within the SFA and popliteal arteries in a single limb which are ≥3 cm and ≤15 cm in cumulative total length (by visual estimation). Lesion must be at least 2 cm from any stented area. Subject is willing to comply with the required follow up visits, testing schedule and medication regimen. Successful wire crossing of lesion. Target vessel reference diameter ≥4 mm and ≤6 mm (by visual estimation). Target lesion(s) can be treated with a maximum of two (2) CVT Everolimus-coated PTA Catheters. At least one patent (less than 50% stenosis) tibio-peroneal run-off vessel confirmed by baseline angiography or prior MR angiography or CT angiography. Life expectancy >1 year Rutherford classification of 2, 3 or 4. Exclusion Criteria: Pregnant or lactating females. Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac or popliteal arteries. Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy. Known intolerance to study medications, everolimus or contrast agents. Doubts in the willingness or capability of the subject to allow follow-up examinations. Subject is actively participating in another investigational device or drug study. History of hemorrhagic stroke within 3 months of procedure. Previous or planned surgical or interventional procedure within 30 days of index procedure. Prior vascular surgery of the target lesion. Lesion length is <3 cm or >15 cm or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured. Known inadequate distal outflow. Significant inflow disease. Acute or sub-acute thrombus in target vessel. Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloons, brachytherapy, lithotripsy). Outflow arteries (distal popliteal, anterior or posterior tibial or peroneal arteries) with significant lesions (≥ 50% stenosis) may not be treated during the same procedure. Treatment of the contralateral limb during the same procedure or within 30 days of the study procedure. Rutherford classification of 0, 1, 5 or 6 Presence of prohibitive calcification that precludes adequate PTA treatment. Subjects held in custody in an institution by official or court order. Subject is not covered by any medical insurance coverage.
Facility Information:
Facility Name
Polyclinique Les Fleurs
City
Ollioules
ZIP/Postal Code
83190
Country
France
Facility Name
Hôpital Paris Saint Joseph
City
Paris
ZIP/Postal Code
75014
Country
France
Facility Name
Hôpital Nord Laennec - CHU de Nantes
City
Saint-Herblain
ZIP/Postal Code
44800
Country
France
Facility Name
Clinique Pasteur
City
Toulouse
ZIP/Postal Code
31300
Country
France
Facility Name
Vivantes Klinikum Neukölln
City
Berlin
ZIP/Postal Code
12351
Country
Germany
Facility Name
Jüdisches Krankenhaus Berlin
City
Berlin
ZIP/Postal Code
13347
Country
Germany
Facility Name
DIAKO Krankenhaus Flensburg
City
Flensburg
ZIP/Postal Code
24939
Country
Germany
Facility Name
Romed Klinikum Rosenheim
City
Rosenheim
ZIP/Postal Code
83022
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery

We'll reach out to this number within 24 hrs